Navigation Links
Verenium Announces $22.5 Million, Five-Year Secured Financing
Date:12/10/2012

ment team," said Richard Pines, a Partner of Athyrium. "We believe this transaction enables Verenium to continue to deploy its proven technology by creating highly differentiated enzyme products across a wide range of sectors and industrial applications."

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

About Athyrium Opportunities Fund

Athyrium Opportunities Fund is a New York-based fund focusing on investment opportunities in the global healthcare sector. The Athyrium investment team has substantial healthcare investment experience across a wide range of asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across healthcare verticals, including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies' capital needs.

Forward Looking Statements For Verenium

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to commercialize its products, enhance its manufacturing capabilities, capture near-term and longer-term growth and prospects, and reach profitability.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic fo
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... , July 24, 2015 Equity ... PDL BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), ... research report on PDL BioPharma can be accessed at ... NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
(Date:7/23/2015)... Chicago, IL (PRWEB) , ... July 23, 2015 , ... ... family member, is pivotal in the management of a brain tumor diagnosis. The American ... family members at the ABTA’s 2015 Patient and Family Conference, July 24-25 in Chicago. ...
(Date:7/23/2015)... ... 2015 , ... July 23, 2015, Chicago - Advances in ... with fewer side effects, according to Erik P. Sulman, MD, PhD, associate professor ... American Brain Tumor Association (ABTA) National Patient and Family Conference in Chicago, July ...
Breaking Biology Technology:Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3
... financial numbers for the end of fiscal 2005 on Thursday, ... ,Revenues were $8.3 million, an 89 percent increase over the ... to multiple unit sales, repeat purchases, new product offerings and ... however, and the company posted a loss of $4.2 million, ...
... Wisconsin in the next ten years, according to a proposal ... reach the Senate for a vote this month. State Senator ... in Wisconsin that would be regulated similarly to airports. , ... to regulate private space travel in the area, receive any ...
... investors in early-stage companies has shown results in its first ... so far applied for $1.8 million of the $3 million ... figures show. But of the $3.5 million in tax credits ... ,"We knew there would be a lag on the venture ...
Cached Biology Technology:Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3Act 255 heats up angel investment in 2005, though VC involvement lags 2Act 255 heats up angel investment in 2005, though VC involvement lags 3
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Providing food security, one of the greatest challenges ... the developing world, where crop destruction by drought, disease ... risk of hunger. Scientists at the University of ... on cowpea, a protein-rich legume crop of immense importance ...
... NJ Uncover the neural communication links involved in ... it may become possible to reverse the breakdown of ... multiple sclerosis, spinal cord injuries, diabetes and cancers of ... the New Jersey Commission on Spinal Cord Injury and ...
... 14 satellites currently in orbit and the National Aeronautics ... been able to observe the Earths environment to help ... The use of remote sensing technology aids specialists ... common and deadly infectious diseases today such as Ebola, ...
Cached Biology News:UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 2UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 3UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 4Rutgers scientist's research reveals critical knowledge about the nervous system 2NASA technology helps predict and prevent future pandemic outbreaks 2